These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15816854)

  • 41. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
    Chiang MC; Chen CM; Lee MR; Chen HW; Chen HM; Wu YS; Hung CH; Kang JJ; Chang CP; Chang C; Wu YR; Tsai YS; Chern Y
    Hum Mol Genet; 2010 Oct; 19(20):4043-58. PubMed ID: 20668093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model.
    Bode FJ; Stephan M; Wiehager S; Nguyen HP; Björkqvist M; von Hörsten S; Bauer A; Petersén A
    Behav Brain Res; 2009 Dec; 205(1):175-82. PubMed ID: 19573560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice.
    Klapstein GJ; Levine MS
    J Neurophysiol; 2005 Feb; 93(2):758-65. PubMed ID: 15371492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease.
    Popoli P; Pèzzola A; Reggio R; Caporali MG; Scotti de Carolis A
    Eur J Pharmacol; 1994 May; 257(1-2):R5-6. PubMed ID: 8082686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease.
    Vázquez-Manrique RP; Farina F; Cambon K; Dolores Sequedo M; Parker AJ; Millán JM; Weiss A; Déglon N; Neri C
    Hum Mol Genet; 2016 Mar; 25(6):1043-58. PubMed ID: 26681807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice.
    Bayram-Weston Z; Jones L; Dunnett SB; Brooks SP
    Brain Res Bull; 2012 Jun; 88(2-3):104-12. PubMed ID: 21801812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
    Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
    Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.
    Tabrizi SJ; Workman J; Hart PE; Mangiarini L; Mahal A; Bates G; Cooper JM; Schapira AH
    Ann Neurol; 2000 Jan; 47(1):80-6. PubMed ID: 10632104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxidative damage in Huntington's disease.
    Segovia J; Pérez-Severiano F
    Methods Mol Biol; 2004; 277():321-34. PubMed ID: 15201466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6/2 mouse model of Huntington's disease.
    Rolfes S; Munro DAD; Lyras EM; Matute E; Ouk K; Harms C; Böttcher C; Priller J
    Neurobiol Dis; 2020 Oct; 144():105024. PubMed ID: 32702387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
    Wang N; Lu XH; Sandoval SV; Yang XW
    J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease.
    García-Forn M; Martínez-Torres S; García-Díaz Barriga G; Alberch J; Milà M; Azkona G; Pérez-Navarro E
    Neurobiol Dis; 2018 Dec; 120():88-97. PubMed ID: 30176350
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.
    Cherny RA; Ayton S; Finkelstein DI; Bush AI; McColl G; Massa SM
    J Huntingtons Dis; 2012; 1(2):211-9. PubMed ID: 25063332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain.
    Datson NA; González-Barriga A; Kourkouta E; Weij R; van de Giessen J; Mulders S; Kontkanen O; Heikkinen T; Lehtimäki K; van Deutekom JC
    PLoS One; 2017; 12(2):e0171127. PubMed ID: 28182673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington's disease.
    Chen CY; Chou FY; Chang YG; Ho CJ; Wu KC; Hsu CL; Chern Y; Lin CJ
    Neurobiol Dis; 2023 Feb; 177():106004. PubMed ID: 36669543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
    Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
    J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
    Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM
    Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.